TKTL1 – Who Is Reporting, and How?
With the growing importance of TKTL1 in the scientific world, reports in the specialist and global press on the latest developments, research and applications of TKTL1 are also increasing.
TKTL1.com aims to provide a daily overview of the reporting around TKTL1.
TKTL1 – Who Is Reporting, and How?
With the growing importance of TKTL1 in the scientific world, reports in the specialist and global press on the latest developments, research and applications of TKTL1 are also increasing.
TKTL1.com aims to provide a daily overview of the reporting around TKTL1.
2024
DUP MAGAZIN | TKTL1: Quantensprung in der Krebs-Früherkennung | 22.02.2024
It controls cell division and plays a crucial role in the development of the brain: TKTL1 has rightly been the focus of science and research for several years. It could also revolutionize the early detection and treatment of cancer. The discoverer of the gene, Dr. Johannes Coy, explains.
2023
IN PACT MEDIAVERLAG | Innovatives Programm zur Früherkennung | 01.02.2023
NORDDEUTSCHER RUNDFUNK | Krebs frühzeitig erkennen: Neue Wege in der Forschung | 05.01.2023
Science is blazing innovative trails in early cancer detection by studying molecular and genetic indicators of cancer. New methods such as a Swedish test that identifies 14 types of cancer through sugar compounds or the PanTum Detect® blood test that analyses macrophages from the blood are raising hopes for earlier and more accurate diagnoses.
2022
NORD WIRTSCHAFT | Die Innovation in der Krebs-Vorsorge | 15.12.2022
In an exclusive interview with NORD WIRTSCHAFT, Folke Tedsen, Head of Benefit and Health Management at HanseMerkur, presents the new supplemental insurance program “Krebs-Scan”. This innovative approach uses the unique PanTum Detect® blood test in combination with imaging techniques to detect potentially dangerous tumors at an early stage. Tedsen discusses the development of the program, the underlying research and the costs for customers, highlighting the potential importance of this innovation for cancer prevention in Germany.
KIIT | The 2022 Nobel Prize In Medicine – Discoveries Of Dr. Svante Pääbo | 08.12.2022
The Swedish scientist Dr. Svante Pääbo, a pioneer of palaeogenomics, was awarded the Nobel prize in Physiology or Medicine. His research has enabled the sequencing of Neanderthal genomes and a deeper understanding of extinct hominins. Particularly noteworthy is the discovery of the TKTL1 gene, which differs from Neanderthals in modern humans by a single amino acid change and plays a key role in neuronal development. These findings contribute significantly to our understanding of the evolution and genetic diversity of modern humans.
BÖRSEN-ZEITUNG | Start-ups hoffen auf Durchbruch der Flüssigbiopsie | 20.11.2022
Liquid biopsies are a promising innovation in cancer detection, despite existing challenges such as the improvement of reliability and recognition by health insurers. In this context, the Hessian company Zyagnum AG is doing pioneering work. Its blood-based cancer screening test is the first to be reimbursed by a German private insurance company, Hanse Merkur. This advance is a significant step towards personalized medicine and could have a decisive impact on the future of oncology.
HANDELSBLATT | Erste Krankenversicherung erstattet umstrittenen Bluttest auf Krebs | 20.10.2022
The PanTum Detect® blood test for early cancer detection is reimbursed for the first time by a private health insurance company, HanseMerkur. This breakthrough is based on encouraging study results that shed light on the possibility of early tumor diagnosis. Criticism comes from the medical community: among other things, the risk of false positive test results is pointed out, which is said to be a high psychological burden for those affected.
PRESSEBOX | HanseMerkur integriert PanTum Detect®-Bluttest in ihrem neuen Krebs-Früherkennungsprogramm „Krebs-Scan“ | 30.09.2022
HanseMerkur Insurance Group is integrating the blood test PanTum Detect® into its new cancer early detection program “Krebs-Scan”. The test, developed by Zyagnum AG, is able to detect certain enzymes produced by most tumors at early stages. Together with modern imaging techniques, this program enables a more comprehensive early cancer detection.
NEUE ZÜRCHER ZEITUNG | Was macht uns intelligent? | 24.09.2022
New research shows differences in the structure of the brain between that of modern humans and that of Neanderthals, particularly with regard to the protein TKTL1, which varies by a point mutation, resulting in a higher number of neurons in modern humans. It is reasonable to assume that TKTL1 and the resulting brain cells are important for human thought.
GENOTOPIA | Un cambio genético en humanos modernos favorece la producción de más neuronas | 14.09.2022
A genetic change in modern humans promotes the production of more neurons, in particular due to a modern variant of the protein TKTL1 that differs from the Neanderthal version by a single amino acid. Researchers at the Max Planck Institute of Cell and Molecular Biology and Genetics have found that this variation boosts the number of neural progenitor cells in the neocortex, an area of the brain that is critical for cognition. This discovery raises new questions about the biological keys that define us as humans and are at the origin of our unique cognitive abilities.
LE MONDE | Evolution : cette petite mutation qui a dopé le cerveau d’« Homo sapiens » | 12.09.2022
A simple change in the composition of a protein in the brain could explain the difference in neuron production in the front part of our cortex compared to Neanderthals. Researchers at Max Planck Institutes in Germany have discovered a difference between our genome and that of Neanderthals which could point to increased cognitive abilities. The protein TKTL1, which has one amino acid different in the human version, plays a central role.
DER STANDARD | Ein neues Puzzleteil im Rätsel um das Aussterben des Neandertalers | 11.09.2022
A crucial difference in brain development between Neanderthals and modern humans has been uncovered by a German research team. Neanderthals produced neural stem cells that were more prone to errors and less efficient at producing neurons. These findings offer insights into the higher cognitive performance of modern humans and may provide the key to understanding the extinction of Neanderthals.
BILD DER WISSENSCHAFT | Neandertaler bildeten weniger Neuronen | 10.09.2022
A study highlights the role of the protein TKTL1 in the development of the human brain. Compared to the Neanderthal version, human TKTL1 promotes the formation of more neurons in the neocortex. This finding could help explain the cognitive superiority of modern humans over Neanderthals.
INDEPENDENT | Study offers first compelling evidence of how humans became more intelligent than Neanderthals | 09.09.2022
Scientists have discovered that a variation in the TKTL1 protein in the brain plays a role in the development of neurons. These findings could help explain the difference in cognitive abilities between modern humans and Neanderthals.
SCIENCE | Human TKTL1 implies greater neurogenesis in frontal neocortex of modern humans than Neanderthals | 09.09.2022
Researchers have found that TKTL1 in the frontal lobe of the brain promotes the formation of neurons. These findings help to better understand the differences in brain development between modern humans and Neanderthals and shed light on the evolutionary factors that have led to our intellectual superiority.
SPIEGEL+ | Entwicklung unseres Gehirns: Ein Zufall namens Mensch | 09.09.2022
Researchers in Dresden may have identified a crucial moment in the evolution of Homo sapiens that took place several hundred thousand years ago. A tiny mutation could be the key to human evolution. This discovery sheds new light on the evolution of our brain and the unique features that distinguish us as a species.
ABC | Un sutil cambio en un único gen permitió a los humanos modernos generar más neuronas que los neandertales | 08.09.2022
Tiny genetic changes in the TKTL1 gene may have given modern humans a crucial advantage by enabling the formation of a greater number of neurons in the brain’s neocortex. An international group of researchers led by Anneline Pinson at the Max Planck Institute for Molecular Cell Biology and Genetics has found that a single amino acid change in the TKTL1 protein sequence is present in modern humans when compared to Neanderthals.
ANSA | Il cervello dei Neanderthal aveva meno neuroni del nostro| 08.09.2022
Various studies conducted by Max Planck Institute show that Neanderthals had fewer neurons than modern humans despite similar brain size, due to a single protein mutation. This sheds new light on the evolution of human cognitive abilities and the role of minimal genetic differences.
MAX-PLANCK-GESELLSCHAFT | Moderne Menschen bilden mehr Nervenzellen im Gehirn als Neandertaler| 08.09.2022
Researchers at Max Planck Institute reveal that a minimal change in the protein TKTL1 causes the increased neuron formation in the brains of modern humans compared to Neanderthals. This finding provides deep insights into the intricacies of human brain evolution and the formation of our cognitive abilities.
NEW YORK TIMES | What Makes Your Brain Different From a Neanderthal’s?| 08.09.2022
According to a study by the Max Planck Institute, a marginal change in the protein TKTL1 leads to a significantly increased neuron formation in modern humans compared to Neanderthals. This genetic difference provides new insights into the fine-tuning of our brain development and the complexity of human cognition.
SÄCHSISCHE ZEITUNG | Dresdner Forscher finden heraus, was das Gehirn des Menschen einzigartig macht | 08.09.2022
Researchers at Dresden’s Max Planck Institute of Molecular Cell Biology and Genetics identify a crucial gene mutation responsible for the unique development of the human brain. This change is missing in Neanderthals as well as in all animal species.
PRESSEBOX | Tübinger Forscher zeigen: PanTum Detect®-Bluttest weist erhöhte TKTL1 und DNaseX (Apo10) Werte bei Kindern mit Neuroblastom nach | 20.08.2022
A study by Tübingen’s Eberhard Karls University shows that PanTum Detect® blood test can detect elevated levels of the tumor markers TKTL1 and DNaseX (Apo10) in 94.7% of the examined children and adolescents with neuroblastoma.
PRESSEBOX | UKE-Studie zeigt: PanTum Detect®-Test ebnet den Weg für zielgerichteten Einsatz bildgebender Verfahren zur Krebsfrüherkennung | 29.07.2022
A study at Eppendorf University Hospital investigates the use of the PanTum Detect® blood test for early cancer detection in combination with imaging procedures. The results show that malignant tumors or premalignant lesions were identified in subsequent imaging in 82 percent of participants who tested conspicuously in the blood test.
Older
DER SPIEGEL | Das Menschen-Gen | 11.07.2020
A tiny genetic mutation may have triggered the accelerated brain growth and paved the way for the evolution of Homo sapiens. These conclusions are based on genetic experiments with mice and monkeys, which show that subtle genetic adaptations can have far-reaching effects on the way a species evolves.
DER SPIEGEL | Wie der Mensch zum Menschen wurde | 10.07.2020
German scientists, led by Wieland Huttner, a researcher from Dresden, are taking aim at a crucial mutation in the genetic code that may have initiated the evolutionary path from apes to humans. The role of such a small genetic change underscores the complexity and subtlety of the mechanisms that influenced our evolution.
MT IM DIAGLOG | Neuer Bluttest PanTum Detect | 03.08.2018
PanTum Detect blood test makes it possible to obtain indications of all solid tumors based on a blood sample. This test uses the body’s own immune system to detect tumors and represents a potential opportunity for comprehensive cancer screening. Due to its ease of use, safety and cost-effectiveness, it could be used annually to detect locally growing tumors at an early stage.
CCHEManager | DKFZ: Zuckerstoffwechsel macht Tumorzellen chemoresistent | 16.10.2011
Recent DKFZ studies confirm a groundbreaking mechanism in cancer treatment: a special sugar metabolism process triggered by the gene TKTL1 can make tumor cells resistant to therapies. By specifically inhibiting this gene, aggressive forms of cancer could be treated more effectively by making tumor cells more sensitive to conventional therapies again while inhibiting cancer cell growth.
PHARMAZEUTISCHE ZEITUNG | Aggressive Krebszellen vergären Zucker | 12.2006
Researchers in Darmstadt, Germany, have discovered that aggressive cancer cells can ferment sugar instead of burning it, which supports their metastasis. These findings confirm an old hypothesis about cancer development and open new avenues for treatments. The enzyme involved, transketolase-like 1 (TKTL1), could be an attractive target for therapeutics. Detection of TKTL1 activity could also help determine the aggressiveness of cancer cells on an individual basis.